5 Recommendations for data collection

5 Recommendations for data collection

5.1 Proposals for further data collection in the Cancer Drugs Fund include:

  • proportion of people having pembrolizumab who have an allogenic stem cell transplant

  • time to allogenic stem cell transplant

  • duration of treatment with pembrolizumab before allogenic stem cell transplant

  • long-term follow-up of people having pembrolizumab with or without subsequent allogenic stem cell transplant (in particular, collection of data on overall survival).

  • National Institute for Health and Care Excellence (NICE)